Prognostic Value of the Haemoglobin-Albumin-Lymphocyte-Platelet Score in Head and Neck Cancer: A Systematic Review and Meta-Analysis.

Clin OtolaryngolJun 21, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Yu Hsin Lin, Hsin Yi Huang, Wan-Lun Hsu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic value of the haemoglobin-albumin-lymphocyte-platelet (HALP) score in head and neck cancer (HNC) patients. Analyzing data from six retrospective cohort studies involving 1759 patients, the study found that higher pretreatment HALP scores were significantly associated with improved overall survival (pooled HR 0.52) and disease-free survival (pooled HR 0.60).

Key findings

  • Higher pretreatment HALP was associated with improved overall survival (pooled HR 0.52, 95% CI 0.41-0.67).
  • Higher HALP also correlated with better disease-free survival (pooled HR 0.60, 95% CI 0.47-0.76).
  • Excluding the metastatic cohort, the overall survival estimate remained similar (HR 0.56, 95% CI 0.45-0.70).
  • Leave-one-out analyses showed stable overall survival estimates (HR range 0.48-0.56).

Why it matters

The HALP score, derived from routine blood tests, may serve as a useful prognostic tool for clinicians assessing survival outcomes in head and neck cancer patients, potentially guiding treatment decisions.

Source

PubMed · PMID 42324208Free full text on PubMed Central

Published in Clin Otolaryngol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.